Consequently, targeting NOTCH2 signaling is under investigation as a therapeutic strategy to combat resistance in various cancers, including breast cancer, lung cancer, and chronic lymphocytic leukemia [59]. The gene discussed is NOTCH2; the disease is lung cancer.